trending Market Intelligence /marketintelligence/en/news-insights/trending/Buc9he6C3c-HEDM45SuaQA2 content esgSubNav
In This List

Ziopharm Oncology names president

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Ziopharm Oncology names president

ZIOPHARM Oncology Inc. said David Mauney has been promoted to president, effective Dec. 13.

Mauney joined the company in 2017 as executive vice president and chief business officer. Previously, Mauney served as managing director at Harvest Capital Strategies LLC.

Boston-based Ziopharm Oncology is a biotechnology company that focuses on acquiring, developing and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens.